NSAID Alzheimer’s Risk-Reduction Effects May Vary By Age – Study
This article was originally published in The Tan Sheet
The apparent effect of non-steroidal anti-inflammatory drugs in reducing the risk of Alzheimer's disease may depend, in part, on a subject's age, Johns Hopkins University researchers suggest in the Sept. 24 issue of Neurology
You may also be interested in...
Warnings detailing the risk of gastrointestinal bleeding with use of aspirin and other non-steroidal anti-inflammatory drugs should replace the current alcohol warning on such products, NDAC members asserted during a meeting in Silver Spring, Md. Sept. 20
A National Institute on Aging study comparing Bayer's OTC Aleve and Merck's Rx Vioxx in Alzheimer's patients will produce data in two and a half years.
NSAID USE LOWERS RELATIVE RISK OF ALZHEIMER's DISEASE among participants of the National Institute on Aging's Baltimore Longitudinal Study of Aging. The study followed 1,686 participants from 1980 to 1995, comparing risks of developing Alzheimer's disease in users of aspirin or other nonsteroidal anti-inflammatory drugs and users of acetaminophen. A report on the study by Walter Stewart, PhD, Johns Hopkins, et al., is published in the March issue of Neurology.